269 related items for PubMed ID: 20200198
1. Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial.
Gonsette RE, Sindic C, D'hooghe MB, De Deyn PP, Medaer R, Michotte A, Seeldrayers P, Guillaume D, ASIIMS study group.
Mult Scler; 2010 Apr; 16(4):455-62. PubMed ID: 20200198
[Abstract] [Full Text] [Related]
2. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V.
Mult Scler; 2010 Apr; 16(4):450-4. PubMed ID: 20150398
[Abstract] [Full Text] [Related]
3. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[Abstract] [Full Text] [Related]
4. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
[Abstract] [Full Text] [Related]
5. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
N Engl J Med; 2006 Mar 02; 354(9):911-23. PubMed ID: 16510745
[Abstract] [Full Text] [Related]
6. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH.
Ann Neurol; 1996 Mar 02; 39(3):285-94. PubMed ID: 8602746
[Abstract] [Full Text] [Related]
7. Assessing disability progression with the Multiple Sclerosis Functional Composite.
Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.
Mult Scler; 2009 Aug 02; 15(8):984-97. PubMed ID: 19667023
[Abstract] [Full Text] [Related]
8. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.
Mult Scler; 2009 Aug 02; 15(8):965-76. PubMed ID: 19465443
[Abstract] [Full Text] [Related]
9. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M.
Lancet Neurol; 2009 Jun 02; 8(6):519-29. PubMed ID: 19409854
[Abstract] [Full Text] [Related]
10. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group.
N Engl J Med; 2010 Feb 04; 362(5):402-15. PubMed ID: 20089954
[Abstract] [Full Text] [Related]
11. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
Bosca I, Coret F, Valero C, Pascual AM, Magraner MJ, Landete L, Casanova B.
Mult Scler; 2008 Jun 04; 14(5):636-9. PubMed ID: 18566027
[Abstract] [Full Text] [Related]
12. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
Arch Neurol; 2008 Feb 04; 65(2):199-204. PubMed ID: 18071030
[Abstract] [Full Text] [Related]
13. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
Clin Ther; 2008 Jun 04; 30(6):1102-12. PubMed ID: 18640466
[Abstract] [Full Text] [Related]
14. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
[Abstract] [Full Text] [Related]
15. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
Bermel RA, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick RA.
Mult Scler; 2010 May 04; 16(5):588-96. PubMed ID: 20167591
[Abstract] [Full Text] [Related]
16. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, Porcel J, Borràs C, Nos C, Rovira A.
Mult Scler; 2009 Oct 04; 15(10):1195-205. PubMed ID: 19797261
[Abstract] [Full Text] [Related]
17. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, Comabella M, Montalban X.
Ann Neurol; 2006 Feb 04; 59(2):344-52. PubMed ID: 16437558
[Abstract] [Full Text] [Related]
18. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up.
Rudick RA, Lee JC, Cutter GR, Miller DM, Bourdette D, Weinstock-Guttman B, Hyde R, Zhang H, You X.
Arch Neurol; 2010 Nov 04; 67(11):1329-35. PubMed ID: 20625068
[Abstract] [Full Text] [Related]
19. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
van der Voort LF, Gilli F, Bertolotto A, Knol DL, Uitdehaag BM, Polman CH, Killestein J.
Arch Neurol; 2010 Apr 04; 67(4):402-7. PubMed ID: 20142519
[Abstract] [Full Text] [Related]
20. New natural history of interferon-beta-treated relapsing multiple sclerosis.
Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP.
Ann Neurol; 2007 Apr 04; 61(4):300-6. PubMed ID: 17444502
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
